StockNews.com Initiates Coverage on TherapeuticsMD (NASDAQ:TXMD)

Equities research analysts at StockNews.com initiated coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a note issued to investors on Saturday. The brokerage set a “hold” rating on the stock.

TherapeuticsMD Stock Performance

TherapeuticsMD stock opened at $1.99 on Friday. The company’s 50-day moving average is $2.29 and its 200-day moving average is $2.37. TherapeuticsMD has a fifty-two week low of $1.95 and a fifty-two week high of $4.72.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. State Street Corp increased its stake in shares of TherapeuticsMD by 13.6% during the 1st quarter. State Street Corp now owns 30,130 shares of the company’s stock worth $113,000 after purchasing an additional 3,600 shares during the last quarter. Principal Financial Group Inc. grew its stake in TherapeuticsMD by 6.3% in the 1st quarter. Principal Financial Group Inc. now owns 123,319 shares of the company’s stock valued at $47,000 after buying an additional 7,263 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in TherapeuticsMD by 18.1% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 52,521 shares of the company’s stock valued at $197,000 after buying an additional 8,064 shares during the last quarter. UBS Group AG grew its stake in TherapeuticsMD by 258.1% in the 2nd quarter. UBS Group AG now owns 18,133 shares of the company’s stock valued at $180,000 after buying an additional 13,069 shares during the last quarter. Finally, Rhumbline Advisers grew its stake in TherapeuticsMD by 4.8% in the 1st quarter. Rhumbline Advisers now owns 312,526 shares of the company’s stock valued at $119,000 after buying an additional 14,372 shares during the last quarter. 30.74% of the stock is currently owned by institutional investors and hedge funds.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY,BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors.